PT-141 vs Melanotan II
Both are synthetic melanocortin-receptor agonists derived from alpha-MSH analogs. PT-141 (bremelanotide) is MC4R-selective, developed specifically for sexual-response research. Melanotan II is a broader MC1R/MC3R/MC4R/MC5R agonist — tanning is its strongest effect, sexual response is a cross-effect. Different target selectivity, dramatically different side-effect load.
For sexual-function research, PT-141 is the better tool — same melanocortin receptor family, cleaner selectivity, designed specifically for that endpoint. Melanotan II produces tanning as its primary effect and sexual response as a cross-effect, with a much heavier side-effect load. PT-141 wins on every axis except 'you specifically want tanning as an endpoint.'
Contender A
PT-141
Also: PT-141 (bremelanotide)
Melanocortin-4 receptor-selective agonist — activates hypothalamic MC4R circuits driving sexual-response pathways without significant melanocyte activation.
- Half-life
- ~2-3 hours
- Primary use
- Sexual-response research (both sexes)
- Dose range
- 1-2 mg SubQ as-needed, pre-activity
- Cost tier
- $$ · Moderate sourcing cost
Contender B
Melanotan II
Also: MT-II
Non-selective melanocortin agonist — hits MC1R (melanocyte / tanning), MC3R, MC4R (sexual / appetite), and MC5R. Broader receptor profile, heavier side-effect load.
- Half-life
- ~30 min plasma
- Primary use
- Tanning research (sexual effect as cross-effect)
- Dose range
- 0.25-1 mg SubQ loading, then maintenance
- Cost tier
- $ · Low sourcing cost
Detailed Comparison
10 attributes side-by-side. Highlighted rows show where one tool has a clear structural edge.
| Attribute | PT-141 (bremelanotide) | MT-II | Edge |
|---|---|---|---|
Receptor selectivity | MC4R-selective | Non-selective (MC1-5) | PT-141 (bremelanotide) |
Primary endpoint | Sexual response | Tanning | Tie |
Sexual-response magnitude | Strong, clean | Strong but with side-effect burden | PT-141 (bremelanotide) |
Tanning effect Right wins this row only if tanning is the research endpoint. | Minimal | Strong | MT-II |
Nausea frequency | Moderate | Very high during loading | PT-141 (bremelanotide) |
Blood-pressure response | Transient elevation | More pronounced elevation | PT-141 (bremelanotide) |
Appetite suppression | Mild | Strong | Tie |
Mole / freckle darkening risk | Minimal | Meaningful — drives most safety concerns | PT-141 (bremelanotide) |
Regulatory status | FDA-approved (women) | Investigational / grey | PT-141 (bremelanotide) |
Research-sourcing cost | Higher per dose | Lower per dose | MT-II |
Practitioner Notes
Sourced from practitioner-validated protocols — not PubMed abstracts.
The selectivity asymmetry is the entire story. PT-141 is MC4R-selective — it was engineered specifically to activate the hypothalamic sexual-response circuit without hitting melanocyte or cardiovascular melanocortin receptors. Melanotan II hits all five melanocortin subtypes, which is why the side-effect list is so much longer — the melanocyte effect (tanning), the MC3R/MC4R appetite effect, and the broader cardiovascular response are all native to the molecule, not off-target.
In research protocols, PT-141 is the right tool for any sexual-function research question. The 'on-demand' dosing pattern (1-2 mg SubQ pre-activity) fits the use case cleanly. Onset is ~45 minutes, effect window ~4-6 hours.
Melanotan II's proper research lane is tanning — MC1R activation drives melanocyte eumelanin production. But the loading protocol (gradually escalating doses until tan develops) produces severe nausea in most research subjects, and the long-term mole-darkening / new-nevus-formation concern is a real dermatology flag. Protocols running Melanotan II include explicit dermatological monitoring.
The worst protocol in the corpus is research subjects using Melanotan II as a sexual-response tool because it's cheaper. PT-141 is more expensive per dose but dramatically cleaner for that endpoint.
Stacking & Switching
Can these be combined? Should you switch from one to the other? Titration considerations.
Stack compatibility: See the “Stacks well” or “Stack compatibility” row in the comparison table above. When the edge column shows Tie, both compounds run together cleanly. When one compound dominates, check the protocol notes for the specific stacking pattern practitioners use.
Switching protocol: The general pattern across practitioner protocols: hold the current dose stable, introduce the new compound at its lowest titration step, run both for a 1-2 week cross-over window, then taper the original. Abrupt switches produce rebound effects as the original compound's steady state clears.
Half-life math: DoseCraft's PK-aware AI models half-life decay and stack overlap across every pairing above. The 20x20 interaction matrix flags contraindications automatically — no manual math, no overlapping-signal blindspots.
Frequently Asked Questions
Indexed for SERP FAQPage rich results.
Do PT-141 and Melanotan II do the same thing?
+
No. PT-141 is MC4R-selective — sexual-response endpoint only. Melanotan II hits all five melanocortin receptors — tanning plus sexual response plus appetite suppression plus cardiovascular effects.
Will PT-141 make me tan?
+
Minimally. MC1R activation is very limited at research doses. If tanning is the research endpoint, Melanotan II is the tool; if sexual response is the endpoint, PT-141 is the tool.
Why does Melanotan II cause so much nausea?
+
Broad melanocortin receptor activation — the MC3R/MC4R effects on the brainstem emesis circuit are pronounced during the loading phase. Research subjects who slow the titration (0.25 mg steps) report meaningfully less nausea.
Is the mole-darkening concern with Melanotan II real?
+
Yes. Existing nevi darken and new nevi can form during protocols. This is why Melanotan II protocols include dermatological monitoring as a standard practice.
Is PT-141 safe for research subjects with cardiovascular history?
+
PT-141 produces transient blood-pressure elevation. Research protocols typically exclude subjects with uncontrolled hypertension. Melanotan II's BP effect is more pronounced and a stronger exclusion factor.
Related Comparisons
Healing
GHK-Cu vs Copper Tripeptide
GHK-Cu and 'copper tripeptide' are the same molecule: a glycyl-L-histidyl-L-lysine tripeptide bound to a copper-2 ion. The terminology overlap confuses newcomers. The meaningful research question isn't which molecule — it's topical vs injectable delivery, because the two routes produce very different biological profiles.
ReadHealing
BPC-157 vs TB-500
BPC-157 is a pentadecapeptide derived from gastric juice with strong localized healing signals, especially in GI and tendon research. TB-500 is a fragment of Thymosin Beta-4 with systemic actin-binding activity driving cell migration, angiogenesis, and broad tissue recovery. Half-lives and delivery profiles are very different; so are their niches.
ReadLongevity
Epitalon vs Thymalin
Epitalon (also called Epithalon) is a synthetic tetrapeptide developed from pineal-gland extract. Thymalin is a polypeptide complex from thymus tissue. Both emerged from the Khavinson longevity research program in Soviet/Russian gerontology. Different organ sources, different mechanisms — pineal / circadian for Epitalon, thymic / immune for Thymalin.
ReadTrack Your Protocol with PK-Aware AI
Compound choice is step one. DoseCraft models half-life decay, stack overlap, and titration paths across 90+ peptides — a pharmacokinetic reasoning layer on top of practitioner-validated protocols.
Track your protocol with PK-aware AI in DoseCraftResearch-only disclaimer: This comparison is for research and educational purposes only. Peptides referenced are sold for research use by third-party suppliers. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease. Always consult a licensed physician before acting on any peptide protocol information.